Document is current

Article History

Accepted: 24 June 2024

First Online: 12 July 2024

Declarations

:

: Dr. Dawson is on the Scientific Advisory Boards of Akili, Inc, Zynerba Pharmaceutical, Inc., Nonverbal Learning Disability Project, and Tris Pharma, Inc., is a consultant to Apple, Inc., Gerson Lehrman Group, and Guidepoint Global, LLC, received speaker fees from WebMD and book royalties from Guilford Press, Oxford University Press, Springer Nature Press. Dr. Dawson has stock interests in Neuvana, Inc. Dr. Dawson and Dr. Carpenter have developed technology, data, and/or products that have been licensed to Apple, Inc. and Cryocell, Inc. and Dawson, Carpenter and Duke University have benefited financially. Dr. Kollins is a full-time employee and equity shareholder in Akili Interactive Labs. Dr. Davis has received research support from Akili Interactive. Drs. Davis, Carpenter, Compton, Eichner, Kollins, Franz, Spanos and Dawson received research support from NICHD P50HD093074 (Dawson, PI). Ms. Marryat and Mr. Lerebours have no competing interests to declare that are relevant to the content of this article.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Duke University Health System Institutional Review Board (protocol #00085434).

: Informed consent was obtained from legal guardians of all participants included in the study.